跳至主要内容
临床试验/IRCT2016020526377N1
IRCT2016020526377N1已完成2 期

Clinical trial to evaluate the role of radioprotection effect of curcumin in peripheral blood lymphocytes of patients with differentiated thyroid carcinoma treated with Iodine-131, by micronucleus assay

Vice Chancellor for Research, Shahid Beheshti University of Medical Sciences0 个研究点目标入组 20 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
no limit 至 no limit(—)
性别
All

入选标准

  • All patients with differentiated thyroid cancer (follicular, papillary or mixed type) don't received destroying dose (ablative dose) of radioiodine up to now; no palpable neck mass; thyroid pathology reported there is no invasion to capsular and lymph areas and blood vessels; body scan with 131-I don’t show any functional tissue in regions other than the thyroid bed; thyroid cancer confirmed by biopsy; all patients have total thyroidectomy; TSH level before administration of radioiodine is higher than 30 IU/ML.
  • exclusion criteria: after treatment with 131 I if there is abnormal tissue absorption of iodine in other areas of the thyroid bed; if patients after taking the first capsule of curcumin had a headache and dizziness; patient will be excluded.

排除标准

  • 未提供

研究者

发起方
Vice Chancellor for Research, Shahid Beheshti University of Medical Sciences

相似试验